Three-year results from the 80 patients in the pilot part of the SPYRAL HTN-ON MED trial confirms that renal denervation with Medtronic plc’s Symplicity Spyral radiofrequency ablation system produces durable, clinically significant reductions in blood pressure in patients with otherwise uncontrolled hypertension.
SPYRAL HTN ON-MED is a 340-patient sham-controlled trial comparing renal denervation with Symplicity Spyral to medication alone in patients whose hypertension remains uncontrolled despite taking a standard regimen of up to three antihypertensive drugs. SPYRAL HTN ON-MED includes an 80-patient pilot part and a 260-patient pivotal part